Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

Michael G. Thomas, Manu De Rycker, Myriam Ajakane, Sébastian Albrecht, Ana Isabel Álvarez-Pedraglio, Markus Boesche, Stephen Brand, Lorna Campbell, Juan Cantizani-Perez, Laura A. T. Cleghorn, Royston C. B. Copley, Sabrinia D. Crouch, Alain Daugan, Gerard Drewes, Santiago Ferrer, Sonja Ghidelli-Disse, Silvia Gonzalez, Stephanie L. Gresham, Alan P. Hill, Sean J. HindleyRhiannon M. Lowe, Claire J. MacKenzie, Lorna MacLean, Sujatha Manthri, Franck Martin, Juan Miguel-Siles, Van Loc Nguyen, Suzanne Norval, Maria Osuna-Cabello, Andrew Woodland, Stephen Patterson, Imanol Pena, Maria Teresa Quesada-Campos, Iain H. Reid, Charlotte Revill, Jennifer Riley, Jose Ramon Ruiz-Gomez, Yoko Shishikura, Frederick R. C. Simeons, Alasdair Smith, Victoria C. Smith, Daniel Spinks, Laste Stojanovski, John Thomas, Stephen Thompson, Tim Underwood, David W. Gray, Jose M. Fiandor, Ian H. Gilbert, Paul G. Wyatt (Lead / Corresponding author), Kevin D. Read (Lead / Corresponding author), Timothy J. Miles (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)
346 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science